Year: 2019
Type: article
Abstract: Genetically engineered T cells have shown promising activity in the treatment of cancer. However, these cells are also potentially susceptible to immune-suppressive pathways in the tumor microenvironment that may limit their efficacy. In this issue of the JCI, Yamamoto et al. describe a new cellular engineering approach to prevent Fas-mediated inhibition of T cell function, which may be exploited to improve cellular therapy for cancer.
DOI: 10.1172/jci127581
Author: Madhav V. Dhodapkar
Institutions: Emory University, Winship Cancer Institute
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G1489263424, G9000104700
OpenAlex ID: W2917868049